ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer October 23, 2026 8:00 AM EDT
Company Participants
Dominic Piscitelli – Chief Financial Officer
Jacob Chacko – President, CEO & Director
Lori Friedman – Chief Scientific Officer
Pratik Multani – Chief Medical Officer
Keith Lui – Senior VP of Commercial & Medical Affairs
Conference Call Participants
Joshua Sabari
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Farzin Haque – Jefferies LLC, Research Division
Derek Archila – Wells Fargo Securities, LLC, Research Division
Charles Kirby
Asthika Goonewardene – Leerink Partners LLC, Research Division
Joohwan Kim – Citigroup Inc., Research Division
Paul Jeng – Guggenheim Securities, LLC, Research Division
Kristin K.
Presentation
Operator
Good day, and thank you for standing by. Welcome to the ORIC Enozertinib Program Update Call. [Operator Instructions] Please be advised that today’s conference is being recorded. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Dominic Piscitelli, CFO.
Dominic Piscitelli
Chief Financial Officer
Good afternoon, and welcome to the ORIC Pharmaceuticals Enozertinib Program Update Conference Call. Earlier today, we issued a press release highlighting updated data from our ongoing Phase Ib study of enozertinib in first-line non-small cell lung cancer patients with EGFR atypical mutations. You can find the press release on the Investor page of oricpharma.com. We have prerecorded our prepared remarks, after which we will host a live Q&A session.
Before we begin, starting on Slide 2, during this conference call, we will be making forward-looking statements, including those based on our current expectations and projections about future events and trends that may affect our business, utilizing data available to us as of the cutoff date set forth on the applicable slide. ORIC’s actual results may differ materially from those expressed in or indicated by such forward-looking statements. For a description of risk factors associated with investing
